Skip to main content
. Author manuscript; available in PMC: 2015 Nov 12.
Published in final edited form as: Vaccine. 2014 Sep 20;32(48):6527–6536. doi: 10.1016/j.vaccine.2014.08.065

Fig. 7.

Fig. 7

Microarray analysis for ROb-12, a RM protected against multiple low-dose challenges with a heterologous R5 SHIV-C. Hierarchical clustering and heat map analysis of differentially expressed genes in the lymph node (A) and gut (B). There were 28 and 57 genes in the lymph node (LN) and gut biopsies, respectively, that were differentially expressed after vaccination and virus challenges (AC) compared to the before vaccination (BV). The analysis uses a significance threshold of false discovery rate <5% and log2 fold-change of >2.